SKVI - Skinvisible, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.1025
+0.0025 (+2.50%)
At close: 3:25PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.1000
Open0.1001
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1001 - 0.1025
52 Week Range0.0120 - 0.2700
Volume484
Avg. Volume1,876
Market Cap458,353
Beta (5Y Monthly)-1.24
PE Ratio (TTM)N/A
EPS (TTM)-0.5700
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • ACCESSWIRE

    Skinvisible Announces License Agreement

    LAS VEGAS, NV / ACCESSWIRE / February 13, 2020 / Skinvisible, Inc. ("Skinvisible") (SKVI), is pleased to announce that it has signed a Licensing Agreement with Ovation Science Inc. for the exclusive worldwide rights to its DermSafe® hand sanitizer made with chlorhexidine gluconate. Skinvisible has signed this License Agreement with Ovation Science subject to the terms of the Agreement which includes three years of exclusivity for an on-going royalty and the option to pay a license fee after the first term. Skinvisible previously signed an exclusive licensing agreement with Ovation Science for the use of its Invisicare polymers for cannabis, hemp and hemp seed oil products.

  • ACCESSWIRE

    Skinvisible Announces Worldwide License Agreement with Quoin Pharmaceuticals in Conjunction with Mutual Termination of Merger Agreement

    LAS VEGAS, NV / ACCESSWIRE / October 22, 2019 / Skinvisible, Inc. ("Skinvisible") (SKVI), is pleased to announce that in conjunction with the mutual cancellation of the pending merger agreement with Quoin Pharmaceuticals, Inc. ("Quoin"), the parties have agreed to a product specific Licensing Agreement. Skinvisible has signed an Exclusive Worldwide License Agreement with Quoin.